1. Home
  2. SEPN vs MCI Comparison

SEPN vs MCI Comparison

Compare SEPN & MCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SEPN
  • MCI
  • Stock Information
  • Founded
  • SEPN 2022
  • MCI 1971
  • Country
  • SEPN United States
  • MCI United States
  • Employees
  • SEPN 75
  • MCI N/A
  • Industry
  • SEPN
  • MCI Trusts Except Educational Religious and Charitable
  • Sector
  • SEPN
  • MCI Finance
  • Exchange
  • SEPN NYSE
  • MCI Nasdaq
  • Market Cap
  • SEPN 553.0M
  • MCI 436.4M
  • IPO Year
  • SEPN 2024
  • MCI N/A
  • Fundamental
  • Price
  • SEPN $12.21
  • MCI $20.66
  • Analyst Decision
  • SEPN Strong Buy
  • MCI
  • Analyst Count
  • SEPN 5
  • MCI 0
  • Target Price
  • SEPN $26.75
  • MCI N/A
  • AVG Volume (30 Days)
  • SEPN 222.3K
  • MCI 40.4K
  • Earning Date
  • SEPN 08-15-2025
  • MCI 01-01-0001
  • Dividend Yield
  • SEPN N/A
  • MCI 8.46%
  • EPS Growth
  • SEPN N/A
  • MCI N/A
  • EPS
  • SEPN N/A
  • MCI 1.82
  • Revenue
  • SEPN $977,000.00
  • MCI N/A
  • Revenue This Year
  • SEPN $3,429.67
  • MCI N/A
  • Revenue Next Year
  • SEPN N/A
  • MCI N/A
  • P/E Ratio
  • SEPN N/A
  • MCI $9.88
  • Revenue Growth
  • SEPN 108.76
  • MCI N/A
  • 52 Week Low
  • SEPN $4.17
  • MCI $12.96
  • 52 Week High
  • SEPN $28.99
  • MCI $19.24
  • Technical
  • Relative Strength Index (RSI)
  • SEPN N/A
  • MCI 44.43
  • Support Level
  • SEPN N/A
  • MCI $20.56
  • Resistance Level
  • SEPN N/A
  • MCI $21.20
  • Average True Range (ATR)
  • SEPN 0.00
  • MCI 0.54
  • MACD
  • SEPN 0.00
  • MCI -0.08
  • Stochastic Oscillator
  • SEPN 0.00
  • MCI 8.13

About SEPN SEPTERNA INC

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

About MCI Barings Corporate Investors

Barings Corporate Investors is a closed-end management investment company. Its investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. The Trust's principal investments are privately placed, below-investment grade, long-term debt obligations, including bank loans and mezzanine debt instruments. The Trust typically purchases these investments, which are not publicly tradable, directly from their issuers in private placement transactions, and the investments are typically made to small or middle market companies.

Share on Social Networks: